Successful clinical trials [54,55,56] confirmed PD-1 as the most effective target and today PD-1/PD-L1 checkpoint blockade therapy is part of the standard therapy for multiple malignancies, such as Hodgkin’s lymphoma and melanoma. Here, CD274 is linked to melanoma.